Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lentiviral Gene Transfer for SCID-X1
NCT03311503Phase 2Recruiting
- Sponsor
- David Williams
- Start
- Feb 2018
- Primary completion
- Jan 2028
- Modality
- Gene Editing, Gene Silencing, Stem Cell Therapies
- Countries
- 1
01
Overview
A Phase 2 trial of autologous CD34+ cells transduced with G2SCID vector in severe combined immunodeficiency (SCID), sponsored by David Williams. Started Feb 2018; status: recruiting.
02
Drugs
autologous CD34+ cells transduced with G2SCID vector
03
Conditions
severe combined immunodeficiency (SCID)
Beyond the preview
Go deeper on NCT03311503.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03311503.